Prime Medicine Announces Pricing of Public Offering

Core Points - Prime Medicine, Inc. announced a public offering of 38,000,000 shares at a price of $3.30 per share, aiming to raise approximately $125.4 million in gross proceeds before expenses [1] - The offering includes a 30-day option for underwriters to purchase an additional 5,700,000 shares [1] - The offering is expected to close around August 1, 2025, pending customary closing conditions [1] Company Overview - Prime Medicine is a biotechnology company focused on developing one-time curative genetic therapies using its proprietary Prime Editing platform, which allows for precise gene editing [6] - The company is advancing a portfolio of investigational therapeutic programs in core areas such as liver, lung, immunology, and oncology, targeting diseases with well-understood biology [7] Offering Details - The shares are being offered under an effective shelf registration statement filed with the SEC on November 3, 2023, and declared effective on November 13, 2023 [3] - The final prospectus supplement will be filed with the SEC and will be available through designated contacts [4]